© 2008 Alexis Corporation
You are here:
Product Lines
>
Cancer
> Antibiotics for Inflammation Research
ALX-350-334
Revised 03-Apr-08
Ascochlorin
SYNONYMS
LL-Z 1272 γ
PRODUCT LINE
Natural Products / Antibiotics
PRODUCT CATEGORY
Antitumor Antibiotics
Ordering Information
Product Numbers:
Format:
Size:
Unit Price:
Quantity:
Add To Cart
ALX-350-334-MC05
0.5 mg
320.00 USD
Product Specification
FORMULA:
C
23
H
29
ClO
4
MW:
404.9
CAS NUMBER:
26166-39-2
RTECS:
VH3707560
SOURCE/HOST:
Isolated from
Acremonium
sp. MST-FP1890.
PURITY:
≥95% (HPLC)
APPEARANCE:
White to light grey powder.
SOLUBILITY:
Soluble in 100% ethanol, methanol, dimethyl formamide or DMSO.
SHIPPING:
AMBIENT
LONG TERM STORAGE:
-20°C
HANDLING:
Protect from light.
HAZARD:
TOXIC.
Product Description
Antitumor antibiotic. Shows antiviral activity. Inhibitor or matrix metalloproteinase 9 (MMP-9). Reduces the inflammatory response to TNF-α in rat vascular smooth muscle cells. May be useful as an antiatherogenic agent.
Product Specific Literature References
Ascochlorin, a new antibiotic, found by the paper-disc agar-diffusion method. I. Isolation, biological and chemical properties of ascochlorin. (Studies on antiviral and antitumor antibiotics. I):
G. Tamura, et al.; J. Antibiot. (Tokyo)
21
, 539 (1968)
Abstract
Ascochlorin derivatives as ligands for nuclear hormone receptors:
M. Togashi, et al.; J. Med. Chem.
46
, 4113 (2003)
Abstract
Ascochlorin inhibits matrix metalloproteinase-9 expression by suppressing activator protein-1-mediated gene expression through the ERK1/2 signaling pathway: inhibitory effects of ascochlorin on the invasion of renal carcinoma cells:
S. Hong, et al.; J. Biol. Chem.
280
, 25202 (2005)
Abstract
;
Full Text
Selective cytotoxicity of ascochlorin in ER-negative human breast cancer cell lines:
K. Sakaguchi, et al.; BBRC
329
, 46 (2005)
Abstract
Ascochlorin suppresses oxLDL-induced MMP-9 expression by inhibiting the MEK/ERK signaling pathway in human THP-1 macrophages:
J.H. Kang, et al.; J. Cell. Biochem.
102
, 506 (2007)
Abstract
Further Categories Containing This Product:
Antibiotics - Antiviral / Anti-HIV
•
MMP Inhibitors
•
Antibiotics for Cytoskeletal Research
•
Antibiotics for Inflammation Research
ALX-350-254
Revised 10-Mar-08
Epoxomicin
PRODUCT LINE
Natural Products / Antibiotics
PRODUCT CATEGORY
Antibiotics - Proteasome / Ubiquitin Modulators
Ordering Information
Product Numbers:
Format:
Size:
Unit Price:
Quantity:
Add To Cart
ALX-350-254-C050
50 µg
132.00 USD
Product Specification
FORMULA:
C
28
H
50
N
4
O
7
MW:
554.7
CAS NUMBER:
134381-21-8
MERCK INDEX:
14:
3630
SOURCE/HOST:
Synthetic.
PURITY:
≥95% (HPLC)
APPEARANCE:
White to off-white solid.
SOLUBILITY:
Soluble in DMSO (15mg/ml); insoluble in water.
ACTIVITY:
k
obs
/[I] = 25’000M
-1
s
-1
versus 20S proteasome.
SHIPPING:
AMBIENT
LONG TERM STORAGE:
-20°C
HANDLING:
Avoid freeze/thaw cycles. Protect from light.
IDENTITY:
Identity determined by
1
H-NMR.
Product Description
Cell permeable, potent and selective proteasome inhibitor originally isolated from
Actinomycetes
strain based on its potent
in vivo
antitumor activity. More potent inhibitor of the chymotrypsin-like activity of the proteasome than lactacystin. Effectively inhibits NF-κB activation
in vitro
and potently blocks inflammation
in vivo
in the mouse ear edema assay.
Product Specific Literature References
Epoxomicin, a new antitumor agent of microbial origin:
M. Hanada, et al.; J. Antibiot. (Tokyo)
45
, 1746 (1992)
Abstract
Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency:
K.B. Kim, et al.; Bioorg. Med. Chem. Lett.
9
, 3335 (1999)
Abstract
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity:
L. Meng, et al.; PNAS
96
, 10403 (1999)
Abstract
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology:
N. Sin, et al.; Bioorg. Med. Chem. Lett.
9
, 2283 (1999)
Abstract
The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses:
K. Schwarz, et al.; J. Immunol.
164
, 6147 (2000)
Abstract
Establishment and some characteristics of epoxomicin (a proteasome inhibitor) resistant variants of the human squamous cell carcinoma cell line, A431:
K. Ohkawa, et al.; Int. J. Oncol.
24
, 425 (2004)
Abstract
Further Categories Containing This Product:
Proteasome / Related Products
•
Antitumor Agents (Enzyme Inhibitors)
•
Anti-inflammatory Agents Other Products
•
Antibiotics for Inflammation Research
•
Antitumor Antibiotics
•
NF-kB Pathway Inhibitors
•
Antibiotics - NF-kB Inhibitors
ALX-380-274
Revised 21-May-08
Erythromycin
PRODUCT LINE
Natural Products / Antibiotics
PRODUCT CATEGORY
Antibiotics for Inflammation Research
Ordering Information
Product Numbers:
Format:
Size:
Unit Price:
Quantity:
Add To Cart
ALX-380-274-G005
5 g
40.00 USD
Product Specification
FORMULA:
C
37
H
67
NO
13
MW:
733.9
CAS NUMBER:
114-07-8
MERCK INDEX:
14:
3681
RTECS:
KF4375000
SOURCE/HOST:
Isolated from
Streptomyces erythreus
.
PURITY:
≥85% (Assay on dry basis)
APPEARANCE:
White to off-white powder.
SOLUBILITY:
Soluble in water (50mg/ml), 100% ethanol or methanol.
SHIPPING:
AMBIENT
LONG TERM STORAGE:
-20°C
HAZARD:
HARMFUL.
Product Description
Macrolide antibiotic. Inhibits protein synthesis (elongation) at the transpeptidation step. Binds to the 23S RNA of the 50S ribosomal subunit. Effective against Gram-negative and Gram-positive bacteria.
Product Specific Literature References
Inducible erythromycin resistance in bacteria:
B. Weisblum; Br. Med. Bull.
40
, 47 (1984)
Abstract
Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells:
Y. Aoki & P.N. Kao; Antimicrob. Agents Chemother.
43
, 2678 (1999)
Abstract
;
Full Text
Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban:
J.Q. Tran, et al.; J. Clin. Pharmacol.
39
, 513 (1999)
Abstract
Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism:
T. Tokairin, et al.; Br. J. Clin. Pharmacol.
60
, 172 (2005)
Abstract
;
Full Text
Related Products
ALX-380-264
EM574
Further Categories Containing This Product:
NF-kB Pathway Inhibitors
•
Anti-inflammatory Agents Other Products
•
Translation Inhibitors
ALX-380-109
Revised 01-Jul-08
Minocycline . hydrochloride
PRODUCT LINE
Natural Products / Antibiotics
PRODUCT CATEGORY
Antibiotics for Angiogenesis Research
Ordering Information
Product Numbers:
Format:
Size:
Unit Price:
Quantity:
Add To Cart
ALX-380-109-M050
50 mg
30.00 USD
Product Specification
FORMULA:
C
23
H
27
N
3
O
7
. HCl
MW:
457.5 . 36.5
CAS NUMBER:
13614-98-7
MERCK INDEX:
14:
6202
RTECS:
QI7630500
SOURCE/HOST:
Semi-synthetic
APPEARANCE:
Yellow crystalline solid.
SOLUBILITY:
Soluble in water (50mg/ml, warm) or DMSO (7mg/ml).
SHIPPING:
AMBIENT
LONG TERM STORAGE:
-20°C
HAZARD:
IRRITANT.
Product Description
Tetracycline derivative with antimicrobial activity. Inhibitor of angiogenesis, apoptosis and poly(ADP-ribose) polymerase-1 (PARP-1). Anti-inflammatory and neuroprotective.
Product Specific Literature References
Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma:
J.L. Frazier, et al.; J. Neurooncol.
64
, 203 (2003)
Abstract
Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases:
J.S. Yao, et al.; Circ. Res.
95
, 364 (2004)
Abstract
Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria:
J. Wang, et al.; J. Biol. Chem.
279
, 19948 (2004)
Abstract
Minocycline up-regulates BCL-2 levels in mitochondria and attenuates male germ cell apoptosis:
M. Castanares, et al.; BBRC
337
, 663 (2005)
Abstract
Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy:
J.K. Krady, et al.; Diabetes
54
, 1559 (2005)
Abstract
Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations:
C.C. Alano, et al.; PNAS
103
, 9685 (2006)
Abstract
Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation:
K. Maier, et al.; Neurobiol. Dis.
25
, 514 (2007)
Abstract
Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration:
J.S. Yao, et al.; Neurochem. Int.
50
, 524 (2007)
Abstract
Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia:
Y. Levkovitz, et al.; Brain Res.
1154
, 154 (2007)
Abstract
Further Categories Containing This Product:
Antibiotics - Apoptosis Inducers & Inhibitors
•
Antibiotics - Nitric Oxide Pathway Modulators
•
NOS Inhibitors (NOS Induction & Enzyme Activity)
•
Antibiotics for Inflammation Research
•
Neuroactive Agents Other Products
•
COX Inhibitors
•
PARP Inhibitors
ALX-380-294
Revised 15-Apr-08
Nadifloxacin
SYNONYMS
9-Fluoro-6,7-dihydro-8-(4-hydroxypiperidino)-5-methyl-1-oxo-1
H
,5
H
-benzo[
ij
]quinolizine-2-carboxylic acid
Jinofloxacin
OPC-7251
Ordering Information
Product Numbers:
Format:
Size:
Unit Price:
Quantity:
Add To Cart
ALX-380-294-M250
250 mg
90.00 USD
ALX-380-294-G001
1 g
270.00 USD
Product Specification
FORMULA:
C
19
H
21
FN
2
O
4
MW:
360.4
CAS NUMBER:
124858-35-1
MERCK INDEX:
14:
6345
PURITY:
≥98% (Assay)
APPEARANCE:
White to yellow crystalline solid.
SOLUBILITY:
Soluble in DMSO.
SHIPPING:
AMBIENT
LONG TERM STORAGE:
-20°C
Product Description
Fluoroquinolone with broad spectrum activity against Gram-negative and Gram-positive bacteria. Inhibits the generation of O
2-
and OH radicals by neutrophils. Inhibits the production of inflammtory cytokines.
Product Specific Literature References
Studies on antibacterial agents. I. Synthesis of substituted 6,7-dihydro-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acids:
H. Ishikawa, et al.; Chem. Pharm. Bull.
37
, 2103 (1989)
Abstract
Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base:
I. Kurokawa, et al.; J. Am. Acad. Dermatol.
25
, 674 (1991)
Abstract
Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris:
K. Vogt, et al.; Eur. J. Clin. Microbiol. Infect. Dis.
11
, 943 (1992)
Abstract
Effect of nadifloxacin on neutrophil functions:
H. Akamatsu, et al.; J. Int. Med. Res.
23
, 19 (1995)
Abstract
Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus:
N. Oizumi, et al.; J. Infect. Chemother.
7
, 191 (2001)
Abstract
Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections:
P. Nenoff, et al.; Chemotherapy
50
, 196 (2004)
Abstract
Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes:
K. Kuwahara, et al.; J. Dermatol. Sci.
38
, 47 (2005)
Abstract
Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771:
M.R. Jacobs & P.C. Appelbaum; Expert Opin. Pharmacother.
7
, 1957 (2006)
Abstract
Further Categories Containing This Product:
Antibiotics - Topoisomerase Inhibitors
•
Antibiotics - DNA Replication Inhibitors
•
Antibiotics for Inflammation Research
ALX-380-060
Revised 11-Jul-08
Tetracycline . hydrochloride
PRODUCT LINE
Natural Products / Antibiotics
PRODUCT CATEGORY
Other Antibiotics - DNA Regulation / Transcription
Ordering Information
Product Numbers:
Format:
Size:
Unit Price:
Quantity:
Add To Cart
ALX-380-060-G005
5 g
20.00 USD
Product Specification
FORMULA:
C
22
H
24
N
2
O
8
. HCl
MW:
444.5 . 36.5
CAS NUMBER:
64-75-5
MERCK INDEX:
14:
9196
RTECS:
QI9100000
APPEARANCE:
Yellow solid.
SOLUBILITY:
Soluble in water, methanol or 100% ethanol.
SHIPPING:
AMBIENT
LONG TERM STORAGE:
+4°C
HANDLING:
Protect from light and moisture.
HAZARD:
IRRITANT.
Product Description
Broad-spectrum antibiotic with anti-inflammatory activity. Blocks bacterial protein synthesis by inhibiting binding of aminoacyl tRNA to A-site of ribosomes. Tetracycline-controlled systems are used to control gene expression on transgenic mice. Marker of bone formation.
Product Specific Literature References
Clinical and laboratory observations of a new antibiotic, tetracycline:
M. Finland, et al.; J. Am. Med. Assoc.
154
, 561 (1954)
Abstract
Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance:
I. Chopra & M. Roberts; Microbiol. Mol. Biol. Rev.
65
, 232 (2001)
Abstract
Tetracyclines: nonantibiotic properties and their clinical implications:
A. N. Sapadin & R. Fleischmajer; J. Am. Acad. Dermatol.
54
, 258 (2006)
Abstract
A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide:
R. Lindsay, et al.; J. Bone Miner. Res.
21
, 366 (2006)
Abstract
Tetracycline-controlled genetic switches:
R. Sprengel & M. T. Hasan; Handb. Exp. Pharmacol.
178
, 49 (2007)
Abstract
Anti-inflammatory activity of tetracyclines:
G. Webster & J. Q. Del Rosso; Dermatol. Clin.
25
, 133 (2007)
Abstract
Further Categories Containing This Product:
tRNA / Related Products
•
Antibiotics for Inflammation Research
•
Antibiotics - Apoptosis Inducers & Inhibitors
•
Translation Inhibitors
© 2008 ALEXIS Corporation,
Privacy Policy
,
Disclaimer
,
Feedback
header picture ©
micronaut.ch
, another
CS2
website
